Xencor Inc (XNCR)
ROA
Obliczenia
|
2023/Q4 (31 gru 2023) |
2023/Q3 (30 wrz 2023) |
2023/Q2 (30 cze 2023) |
2023/Q1 (31 mar 2023) |
2022/Q4 (31 gru 2022) |
2022/Q3 (30 wrz 2022) |
2022/Q2 (30 cze 2022) |
2022/Q1 (31 mar 2022) |
||
|---|---|---|---|---|---|---|---|---|---|
| Zysk netto (ttm) | w tys. USD | -126 087 | -119 027 | -127 517 | -139 538 | -55 181 | 29 921 | 22 489 | 108 712 |
| Aktywa razem | w tys. USD | 952 692 | 778 430 | 778 121 | 803 411 | 846 266 | 835 269 | 851 325 | 857 922 |
| ROA | -13,23% | -15,29% | -16,39% | -17,37% | -6,52% | 3,58% | 2,64% | 12,67% |
2023/Q4 obliczenia
ROA = Zysk netto (ttm) ÷ Aktywa razem
= $-126 087K ÷ $952 692K
= -13,23%
Analiza porównawcza
2023/Q4
Nazwa spółki
Symbol
ROA
Xencor Inc
XNCR
-13,23%
Amphastar Pharmaceuticals Inc
AMPH
9,09%
Arcus Biosciences Inc
RCUS
-28,04%
Catalyst Pharmaceuticals Inc
CPRX
15,19%
Dynavax Technologies Corp.
DVAX
-0,64%
Harmony Biosciences Holdings Inc
HRMY
15,88%
Ironwood Pharmaceuticals Inc
IRWD
-212,76%
Ligand Pharmaceuticals, Inc.
LGND
6,63%
Myriad Genetics, Inc.
MYGN
-22,97%
Pacira BioSciences Inc
PCRX
2,66%
Supernus Pharmaceuticals Inc
SUPN
0,10%